EY says it will be 'carbon negative' by the end of the year – here's its 7-point plan for getting there

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. EY office in London. Jack Taylor/Stringer/Getty ImagesErnst & Young aims to be carbon negative this year, cut emissions by 40%, and be net zero in 2025. Steve Varley, EY chief sustainability officer, told Insider he was inspired by Microsoft's strategy. The company plans on removing more carbon dioxide from the atmosphere than it emits through seven key goals. Visit Business Insider's homepage for more stories. Accounting giant Ernst & Young announced Monday plans to become carbon negative in 2021, "net zero" in 2025 and cut its total emissions by 40% with seven key commitments. The London-headquartered firm achieved its goal of becoming carbon neutral in 2020, but after reviewing the science and talking to the company's climate change experts, it became clear that being carbon neutral wasn't enough. Steve Varley, EY's chief sustainability officer who was appointed in July 2020, told Insider the company emitted 1.1 million tonnes of carbon dioxide in 2019. The travel restrictions brought on by the coronavirus crisis has meant these emissions have fallen to 769,ooo tonnes, but Varley said EY's commitment is "regardless" of the impact of the pandemic.  "Our commitment is to remove more carbon dioxide from the atmosphere than we emit every To keep reading about EY says it will be 'carbon negative' by the end of the year – here's its 7-point plan for getting there, Click on the link. Seoul, Korea
http://dlvr.it/RrGDNR

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint